

ECNP Supports European Research Projects



conect4children

Paving the future for the treatment of children through a pan-European clinical network

THE CHALLENGE Fragmentation and redundancy between sponsors, sites and countries; difficulties in involving young patients and families; the need to include collaborative expert inputs in the development of innovative paediatric trials for many disorders: all combine to make paediatric clinical trials particularly complex and challenging.



THE GOAL To build a sustainable, integrated infrastructure for the efficient and swift delivery of high-quality, innovative, “regulatory grade” clinical trials in children and adolescents across all conditions – including psychiatric disorders.



The c4c consortium at the General Assembly Meeting in Rome, May 2019

THE PLAN The project is creating a sustainable network to optimise the delivery of clinical trials in children by offering a single point of contact for sponsors, sites and investigators. Collaborating with experienced specialty networks and gaining high-quality input into study design through advice from our expert groups. The project has developed an education and training platform to shape the future leaders of paediatric drug development, promoting consistent approaches, aligning quality standards and coordination of sites at national and international levels.



THE IMPACT To facilitate the development of new medicines and therapies for the entire paediatric population

ECNP AND c4c ECAPN, an initiative of the ECNP Child and Adolescent Neuropsychopharmacology Network and part of the c4c consortium, aims to identify unmet needs and to improve the treatment of children and adolescents with psychiatric disorders in the clinical practice.

Term: 1 May 2018 – 30 April 2024
 Website: <https://conect4children.org>
 Twitter: @c4c_network



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This infographic reflects only the author's views and neither the IMI 2 JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.

